Experienced Physicians
John S. Carman, M.D.
   Medical Director and Founder of Carman Research
   Clinical research for ov...
Dedicated and Stable Team
Edwinia Paden-Johnson
   Medical Records Coordinator
   With Carman Research for 26 years
Casey ...
Broad Experience
Therapeutic Area                         Number of Studies (by 2009)
Major Depressive Disorder           ...
Clinical Trial Phase Experience
Phase of Development   Number (by 2009)
Phase Ib/IIa           10
Phase II               1...
Excellent Enrollment
Indication                          Screened   Randomized
Major Depressive Disorder           35     ...
Excellent Retention
Indication                          Randomized   Completed
                                           ...
Quality Data
Physicians integrally involved in every visit and
administer rating scales
Very low rate of rater switching d...
Proven Results
In its 28 years of existence in Northwest Atlanta,
Carman Research has conducted clinical studies
for more ...
Carman Research
Carman Research
Upcoming SlideShare
Loading in …5
×

Carman Research

2,066 views

Published on

  • Be the first to comment

  • Be the first to like this

Carman Research

  1. 1. Experienced Physicians John S. Carman, M.D. Medical Director and Founder of Carman Research Clinical research for over 38 years Clinical trial investigator for over 300 clinical trials Board certified in psychiatry Well published with previous NIMH and academic experience (University of Alabama) Nathan Andrew Shapira, M.D., Ph.D. Clinical research for over 12 years Board certified in psychiatry; Ph.D. in neuropathology Well published with previous industry (Solvay Pharmaceuticals and Tikvah Therapeutics) and academic experience (University of Florida)
  2. 2. Dedicated and Stable Team Edwinia Paden-Johnson Medical Records Coordinator With Carman Research for 26 years Casey Chacona Senior Research Coordinator With Carman Research for 10 years Becky Empric and Robin Swinks Research Coordinators With Carman Research for 7 and 3 years, respectively Marc McLaughlin and Lori Johnson Office Administration and Recruitment With Carman Research for 3 years
  3. 3. Broad Experience Therapeutic Area Number of Studies (by 2009) Major Depressive Disorder 139 (including 4 TRD) Schizophrenia/Schizoaffective Disorder 44 Generalized Anxiety Disorder 37 Bipolar Disorder 27 (Mania); 15 (Dep); 4 (Proph) Alzheimer’s Disorder 11 Panic Disorder 6 Insomnia 5 Social Anxiety Disorder 3 Obsessive-Compulsive Disorder 3 Adult Attention Deficit Disorder 3 Chronic Pain and Fibromyalgia 3 Obesity 1
  4. 4. Clinical Trial Phase Experience Phase of Development Number (by 2009) Phase Ib/IIa 10 Phase II 112 Phase III 140 Phase IV 39
  5. 5. Excellent Enrollment Indication Screened Randomized Major Depressive Disorder 35 30 Major Depressive Disorder 19 15 Major Depressive Disorder 22 16 Major Depressive Disorder 36 25 Major Depressive Disorder (ext) 15 10 Major Depressive Disorder 56 36 Generalized Anxiety Disorder 12 11 Generalized Anxiety Disorder 22 21 Generalized Anxiety Disorder 13 12 Generalized Anxiety Disorder 26 22 Bipolar Disorder, Depression 14 12 Overall for 2008-2009 (18 months) 270 210 (78%)
  6. 6. Excellent Retention Indication Randomized Completed (> 8 weeks) Major Depressive Disorder 30 25 Major Depressive Disorder 15 12 Major Depressive Disorder 16 9 Major Depressive Disorder 25 17 Major Depressive Disorder (ext) 10 6 Major Depressive Disorder 36 35 Generalized Anxiety Disorder 11 9 Generalized Anxiety Disorder 21 18 Generalized Anxiety Disorder 8 7 Generalized Anxiety Disorder 22 18 Bipolar Disorder, Depression 12 9 Overall for 2008-2009 (18 months) 210 165 (80%)
  7. 7. Quality Data Physicians integrally involved in every visit and administer rating scales Very low rate of rater switching during study Electronic data capture entered efficiently Low placebo response rates: 24% for Major Depressive Disorder (5 studies) 30% for Generalized Anxiety Disorder (3 studies) For studies over the past 4 years, with greater than 10 per arm and code breaks available High compliance: In a recent phase II GAD trial with pharmacokinetic Levels, our subjects demonstrated the highest Percent confirmed compliance with study medication.
  8. 8. Proven Results In its 28 years of existence in Northwest Atlanta, Carman Research has conducted clinical studies for more than 60 sponsoring pharmaceutical companies. Carman Research has been involved in pivotal studies leading to approval and/or expansion of indications for 23 psychoactive compounds now on the market, for over 30 different formulations or indications: Abilify Geodon Saphris Aricept Invega Seroquel (IR and XR) Celexa Lexapro Wellbutrin (IR,SR and XL) Depakote Namenda Xanax XR Desyrel (IR and Paxil (IR and CR) Zoloft Contramid) Pristiq Zyprexa Effexor (IR and XR) Prozac Emsam Remeron Exelon Risperdal

×